Physiology & Pharmacology of Dopamine D2-Receptors:Their Implications in Dopamine-Substitute Therapy for Park
Neurol 39:1106-1108, Mercuri,N.B.,et al, 1989
Postmortem Analysis of Adrenal-Medulla-to-Caudate Autograft in a Patient with Parkinson's Disease
Ann Neurol 25:607-614, Hurtig,H.,et al, 1989
The Efficacy of (+) -4-Propyl-9-Hydroxynaphthoxazine as Adjunctive Therapy in Parkinson's Disease
JNNP 52:732-735, Weiner,W.J.,et al, 1989
CNS Dysfunction in Fisher's Syndrome
Neurol 39:998-999, Pessin,M.S.,et al, 1989
Neuroleptic Malignant Syndrome, Review of Response to Therapy
Arch Int Med 149:1927-1931, Rosenberg,M.R.&Green,M., 1989
Metoclopramide-Induced Movement Disorders
Arch Int Med 149:2486-2492, Miller,L.G.&Jankovic,J., 1989
Oculogyric Crisis after Metoclopramide Therapy
Optometry and Vision Science 66:179-180, Edward,M.,et al, 1989
Dopamine Agonists, In Parkinson's Disease and Movement Disorders
Urban & Schwarzenberg, Balt, p. 104., Jankovic,J.&Tolosa,E., 1988
Treatment of Patients with Neuropathy and Anti-MAG IgM M-Proteins
Ann Neurol 24:93-97, Nobile-Orazio,E.,et al, 1988
PHNO[ (+) -4-Propyl-9-Hydroxynaphthoxazine]:A New and Effective Anti-Parkinson's Disease Agent
Neurol 38:1541-1545, Muenter,M.D.,et al, 1988
Role of Subcutaneous Apomorphine in Parkinsonian Voiding Dysfunction
Lancet 2:1451-1453, Christmas,T.J.,et al, 1988
Three Patients with Fisher's Syndrome and Normal MRI
Neurol 38:1630-1631, Ropper,A.H., 1988
Serum Antibodies to GM1 Ganglioside in Amytrophic Lateral Sclerosis
Neurol 38:1457-1461, Pestronk,A.,et al, 1988
Hyperprolactinaemia, Common and Treatable
BMJ 297:701-702, Hartog,M.&Hull,M.G.R., 1988
International Symposium on Early Dopamine Agonist Therapy of Parkinson's Disease
Arch Neurol 45:204-208, Kurlan,R., 1988
Immunotherapy of Multiple Sclerosis
Ann Neurol 23:211-223, Weiner,H.L.&Hafler,D.A., 1988
Nosocomial Aseptic Meningitis Associated with Administration of OKT3
JAMA 259:2002-2005, Martin,M.A.,et al, 1988
Pharmacotherapy for Aphasia
Neurol 38:877-879, Albert,M.L.,et al, 1988
Autoantibody Activity in Lambert-Eaton Myasthenic Syndrome
Editorial, Lancet 1:9201988., , 1988
Subcutaneous Apomorphine in Parkinsonian On-Off Oscillations
Lancet 1:403-406, Stibe,C.M.H.,et al, 1988
Acute Upper Airway Obstruction Due to Supraglottic Dystonia Induced by a Neuroleptic
BMJ 297:964-965, Newton-John,H., 1988
A Double-Blind Randomized Crossover Trial of Bromocriptine & Placebo in Restless Legs Syndrome
Ann Neurol 24:455-458, Walters,A.S.,et al, 1988
Pleuropulmonary & Retroperitoneal Fibrosis Associated with Bromocriptine Treatment
JNNP 50:1706-1707, Ward,C.D.,et al, 1987
Extrapyramidal Disturbances Caused by Inappropriate Prescribing
BMJ 295:30-31, Pall,H.S.&Williams,A.C., 1987
Peripheral Neuropathy Associated with Monoclonal IgM Autoantibody
Ann Neurol 22:764-767, Steck,A.J.,et al, 1987
Giant Invasive Prolactinomas
Am J Med 83:995-1002, Murphy,F.Y.,et al, 1987
Minimal Thyroid Ophthalmopathy
Neurol 37:1803-1808, Spector,R.H.&Carlisle,J.A., 1987
Early Combination of Bromocriptine & Levodopa in the Treatment of Parkinson's Disease:A 5-Year Follow-up
Neurol 37:826-828, Rinne,U.K., 1987
Bromocriptine Induced Impotence in Parkinson's Disease
BMJ 295:367-368, Cleves,L., 1987
Metoclopramide-Induced Neuroleptic Malignant Syndrome
Arch Int Med 147:1495-1497, Friedman,L.S.,et al, 1987
Expression of Human Immunodeficiency Virus in Cerebrospinal Fluid of Children with Progressive Encephalopathy
Ann Neurol 21:397-401, Epstein,L.G.,et al, 1987
Treatment of Gilles de la Tourette's Syndrome:Experience in a Predominantly Adult Population
Neurol 37:1828-1833, Mesulam,M.M.&Peterson,R.C., 1987
Expressions of Human Immunodeficiency Virus Antigen (HIV-Ag) in Serum & CSF During Acute & Chronic Infection
Lancet 2:177-180, Goudsmit,J.,et al, 1986
Acute Bilateral Ophthalmoplegia:60 Cases
Neurol 36:279-281, Keane,J.R., 1986
Low-Dose Bromocriptine Therapy in Parkinson's Disease:Double-Blind, Placebo-Controlled Study
Neurol 36:291-293, Staal-Schreinemachers,A.L.,et al, 1986
Dopamine D2 Receptor Density Remains Constant in Treated Parkinson's Disease
Ann Neurol 19:487-492, Guttman,M.,et al, 1986
Immunologic Responses of Progressive Multiple Sclerosis Patients Treated with an Anti-T-Cell Monoclonal Antibody
Neurol 36:777-784, Hafler,D.A.,et al, 1986
Metoclopramide-Induced Parkinsonism in Hemodialysis Patients
Arch Int Med 146:2070-2071, Sirota,R.A.,et al, 1986
Tardive Dyskinesia Associated with High-Dose Intravenous Metoclopramide
NEJM 315:518-519, Breitbart,W., 1986
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Extrapyramidal Reactions with Metoclopramide
BMJ 291:930-932, Bateman,D.N.,et al, 1985
Low-Dose Bromocriptine Therapy in Parkinson's Disease
Arch Neurol 42:586-588, Pfeiffer,R.F.,et al, 1985
Mesulergin (CU32-085) in the Treatment of Parkinson's Disease
Ann Neurol 17:334-336, Pfeiffer,R.F.,et al, 1985
Relapsing Ophthalmoparesis-Sensory Neuropathy Syndrome
Neurol 35:595-596, Kaplan,J.G.,et al, 1985
Placebo-Controlled Study of Mesulergine in Parkinson's Disease
Neurol 35:161-165, Jankovic,J.,et al, 1985
Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas
NEJM 313:656-659, Liuzzi,A.,et al, 1985
Cerebrospinal Fluid Rhinorrhea During Treatment with Bromocriptine for Prolactinoma
Neurol 35:1193-1195, Kok,J.G.,et al, 1985
Neuroleptic Malignant Syndrome
NEJM 313:163-166, Guze,B.H.,et al, 1985
Pimozide for Tourette's Disorder
Medical Letter 27:3-4, , 1985
Prolactinomas
Editorial, BMJ 290:182-1841985., Grossman,A.,et al, 1985